Q32 Bio Inc. is a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis. Q32 Bio Inc., formerly known as Homology Medicines Inc., is based in WALTHAM, Mass.
| Revenue (Most Recent Fiscal Year) | $53.74M |
| Net Income (Most Recent Fiscal Year) | $29.82M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | 7.18 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.33 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 9.81 |
| Pre-Tax Margin (Trailing 12 Months) | 62.87% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | 50.17% |
| Return on Assets (Trailing 12 Months) | 29.49% |
| Current Ratio (Most Recent Fiscal Quarter) | 20.30 |
| Quick Ratio (Most Recent Fiscal Quarter) | 20.30 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $3.56 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.44 |
| Earnings per Share (Most Recent Fiscal Year) | $1.47 |
| Diluted Earnings per Share (Trailing 12 Months) | $3.00 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 29.77M |
| Free Float | 19.51M |
| Market Capitalization | $442.67M |
| Average Volume (Last 20 Days) | 0.42M |
| Beta (Past 60 Months) | 0.21 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 34.46% |
| Percentage Held By Institutions (Latest 13F Reports) | 31.32% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |